Vera Therapeutics, Inc. (VERA)
NASDAQ:VERA
Want to see VERA full AI Analyst Report?
Top Page
Vera Therapeutics
(NASDAQ:VERA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$33.00
▼(-21.99% Downside)
Action:Reiterated
Date:06/03/26
The score is held down primarily by weak financial performance (pre-revenue, accelerating losses and cash burn) and a bearish technical setup (price below key moving averages with negative MACD). A positive offset is the regulatory event that may accelerate atacicept’s approval path, but it does not outweigh current profitability and funding-risk pressures.
Positive Factors
Regulatory progress: FDA alignment
Agreement with the FDA to advance an earlier eGFR analysis materially shortens the regulatory timeline for atacicept. This structural alignment reduces regulatory uncertainty, raises the probability of a near-term sBLA filing, and could accelerate transition from clinical to commercial stage.
Negative Factors
Pre-revenue business model
The company remains pre-revenue with no product sales to offset R&D spending. Long-term value creation depends entirely on successful clinical outcomes and approval of atacicept or other candidates, making cash generation currently non-existent and future revenues binary and uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory progress: FDA alignment
Agreement with the FDA to advance an earlier eGFR analysis materially shortens the regulatory timeline for atacicept. This structural alignment reduces regulatory uncertainty, raises the probability of a near-term sBLA filing, and could accelerate transition from clinical to commercial stage.
Read all positive factors
Vera Therapeutics (VERA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.32B
Dividend YieldN/A
Average Volume (3M)1.14M
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue GrowthN/A
EPS Growth-85.06%
CountryUS
Employees152
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.54
Shares Outstanding71,782,906
10 Day Avg. Volume1,266,908
30 Day Avg. Volume1,139,524
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)5.38
Price to Sales (P/S)0.00
P/FCF Ratio-13.46
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.15K
Enterprise Value/Ebitda-6.92
Forecast
1Y Price Target
$81.10Price Target Upside91.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-6.07
Revenue Forecast (FY)$37.80M
Vera Therapeutics Business Overview & Revenue Model
Company Description
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is at...
How the Company Makes Money
As a clinical-stage biotechnology company, Vera Therapeutics has not commercialized a product and has historically not generated product sales revenue; accordingly, recurring operating revenue from marketed drugs is null. The company’s funding to ...
Vera Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 308.00K | 0.00 | 0.00 | 0.00 | 846.00K | 0.00 |
| EBITDA | -362.77M | -291.62M | -144.42M | -92.18M | -88.91M | -32.41M |
| Net Income | -368.95M | -299.62M | -152.15M | -95.99M | -89.06M | -32.61M |
Balance Sheet | ||||||
| Total Assets | 621.74M | 734.73M | 655.68M | 175.55M | 131.44M | 83.75M |
| Cash, Cash Equivalents and Short-Term Investments | 596.76M | 714.59M | 640.85M | 160.72M | 114.65M | 79.67M |
| Total Debt | 75.03M | 77.31M | 54.64M | 53.71M | 31.29M | 4.92M |
| Total Liabilities | 122.04M | 130.21M | 78.53M | 73.86M | 54.53M | 14.16M |
| Stockholders Equity | 499.70M | 604.52M | 577.15M | 101.69M | 76.91M | 69.59M |
Cash Flow | ||||||
| Free Cash Flow | -293.81M | -241.73M | -135.65M | -92.24M | -67.66M | -23.71M |
| Operating Cash Flow | -293.20M | -241.10M | -134.68M | -92.18M | -67.60M | -23.71M |
| Investing Cash Flow | 41.15M | 194.29M | -425.03M | -39.43M | -70.55M | -4.20M |
| Financing Cash Flow | 311.31M | 308.90M | 606.67M | 133.54M | 101.93M | 53.88M |
Vera Therapeutics Technical Analysis
Negative
42.30
Price Trends
37.63
Negative
40.18
Negative
36.67
Negative
Market Momentum
-1.43
Positive
39.57
Neutral
26.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERA, the sentiment is Negative. The current price of 42.3 is above the 20-day moving average (MA) of 34.91, above the 50-day MA of 37.63, and above the 200-day MA of 36.67, indicating a bearish trend. The MACD of -1.43 indicates Positive momentum. The RSI at 39.57 is Neutral, neither overbought nor oversold. The STOCH value of 26.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VERA.
Vera Therapeutics Risk Analysis
Vera Therapeutics disclosed 86 risk factors in its most recent earnings report. Vera Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vera Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $3.83B | -21.66 | -32.55% | ― | ― | -7.28% | |
52 Neutral | $2.15B | -10.41 | -67.40% | ― | ― | -5.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.74B | -4.47 | -60.70% | ― | 23382.78% | 7.01% | |
47 Neutral | $814.75M | -7.31 | -11.85% | ― | 47.10% | -35.51% | |
45 Neutral | $2.32B | -6.26 | -74.86% | ― | ― | -85.06% | |
45 Neutral | $1.63B | -2.46 | -866.46% | ― | ― | 39.46% |
* Healthcare Sector Average
VERA
Vera Therapeutics
31.75
9.56
43.08%
VRDN
Viridian Therapeutics
15.73
0.87
5.85%
PHVS
Pharvaris
31.59
13.56
75.21%
EWTX
Edgewise Therapeutics
34.84
19.58
128.31%
JANX
Janux Therapeutics Inc
13.51
-12.43
-47.92%
BHVN
Biohaven Ltd.
11.12
-5.95
-34.86%
Vera Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Vera Therapeutics Advances Atacicept Approval Path in IgA Nephropathy
Positive
Jun 2, 2026
On June 2, 2026, Vera Therapeutics, Inc. announced it had reached agreement with the U.S. Food and Drug Administration on a revised, earlier analysis plan for the ORIGIN 3 study’s eGFR endpoint to support potential full approval of atacicept...
Executive/Board ChangesShareholder Meetings
Vera Therapeutics Stockholders Back Board, Governance Proposals
Positive
May 26, 2026
On May 21, 2026, Vera Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, with 71,713,905 shares of Class A common stock entitled to vote as of the March 24, 2026 record date. Stockholders elected three Class II directors—Michae...
Executive/Board Changes
Vera Therapeutics Adds Christopher Hite to Board
Positive
Mar 9, 2026
On March 5, 2026, Vera Therapeutics, Inc. appointed Christopher Hite to its board of directors as a Class III director, with his initial term running through the 2027 annual meeting of stockholders. As part of his compensation, Hite received a non...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.